Yunnan Baiyao Group Co.,Ltd

SZSE:000538 Stock Report

Mkt Cap: CN¥103.9b

We’ve recently updated our valuation analysis.

Yunnan Baiyao GroupLtd Valuation

Is 538 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 538?

Other financial metrics that can be useful for relative valuation.

538 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.6x
Enterprise Value/EBITDA24.2x
PEG Ratio1.4x

Price to Earnings Ratio vs Peers

How does 538's PE Ratio compare to its peers?

The above table shows the PE ratio for 538 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average43.5x
600196 Shanghai Fosun Pharmaceutical (Group)
26.8x20.8%CN¥89.9b
000661 Changchun High-Tech Industries (Group)
20.6x24.1%CN¥83.9b
600085 Beijing Tongrentang
49.2x18.4%CN¥64.4b
600436 Zhangzhou Pientzehuang Pharmaceutical
77.5x19.5%CN¥191.7b
000538 Yunnan Baiyao GroupLtd
39.1x27.6%CN¥103.9b

Price-To-Earnings vs Peers: 000538 is good value based on its Price-To-Earnings Ratio (39.1x) compared to the peer average (43.5x).


Price to Earnings Ratio vs Industry

How does 538's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a24.5%
n/an/an/a

Price-To-Earnings vs Industry: 000538 is expensive based on its Price-To-Earnings Ratio (39.1x) compared to the CN Pharmaceuticals industry average (35.3x)


Price to Earnings Ratio vs Fair Ratio

What is 538's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

538 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39.1x
Fair PE Ratio43.7x

Price-To-Earnings vs Fair Ratio: 000538 is good value based on its Price-To-Earnings Ratio (39.1x) compared to the estimated Fair Price-To-Earnings Ratio (43.7x).


Share Price vs Fair Value

What is the Fair Price of 538 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 000538 (CN¥58.25) is trading above our estimate of fair value (CN¥47.9)

Significantly Below Fair Value: 000538 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 538 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥58.25
CN¥73.26
+25.8%
17.5%CN¥100.20CN¥60.00n/a7
Jan ’24CN¥54.36
CN¥72.55
+33.5%
18.8%CN¥100.20CN¥55.00n/a7
Dec ’23CN¥57.26
CN¥73.28
+28.0%
17.8%CN¥100.20CN¥55.00n/a7
Nov ’23CN¥55.00
CN¥73.63
+33.9%
17.8%CN¥100.20CN¥55.00n/a7
Oct ’23CN¥52.35
CN¥73.66
+40.7%
17.8%CN¥100.20CN¥55.00n/a7
Sep ’23CN¥51.97
CN¥77.75
+49.6%
18.4%CN¥100.20CN¥55.71n/a6
Aug ’23CN¥54.67
CN¥77.75
+42.2%
18.4%CN¥100.20CN¥55.71n/a6
Jul ’23CN¥60.01
CN¥78.42
+30.7%
18.6%CN¥100.20CN¥55.71n/a6
Jun ’23CN¥55.61
CN¥77.62
+39.6%
17.6%CN¥100.20CN¥55.71n/a7
May ’23CN¥54.49
CN¥75.54
+38.6%
17.6%CN¥100.00CN¥55.71n/a7
Apr ’23CN¥57.86
CN¥77.97
+34.8%
13.7%CN¥100.00CN¥65.71n/a7
Mar ’23CN¥64.67
CN¥85.22
+31.8%
12.5%CN¥100.00CN¥71.57n/a6
Feb ’23CN¥64.49
CN¥85.22
+32.2%
12.5%CN¥100.00CN¥71.57n/a6
Jan ’23CN¥74.75
CN¥91.87
+22.9%
20.7%CN¥131.76CN¥71.57CN¥54.367
Dec ’22CN¥63.14
CN¥96.46
+52.8%
22.4%CN¥131.76CN¥71.57CN¥57.268
Nov ’22CN¥64.36
CN¥99.83
+55.1%
21.0%CN¥131.76CN¥71.57CN¥55.007
Oct ’22CN¥69.85
CN¥107.98
+54.6%
18.3%CN¥131.76CN¥71.57CN¥52.357
Sep ’22CN¥65.06
CN¥109.51
+68.3%
17.1%CN¥131.76CN¥71.57CN¥51.977
Aug ’22CN¥70.70
CN¥110.50
+56.3%
16.9%CN¥131.76CN¥71.57CN¥54.677
Jul ’22CN¥85.50
CN¥112.14
+31.2%
16.2%CN¥131.76CN¥71.57CN¥60.017
Jun ’22CN¥89.29
CN¥112.14
+25.6%
16.2%CN¥131.76CN¥71.57CN¥55.617
May ’22CN¥76.82
CN¥110.89
+44.3%
15.6%CN¥131.76CN¥71.57CN¥54.498
Apr ’22CN¥86.59
CN¥111.34
+28.6%
15.7%CN¥131.76CN¥71.57CN¥57.868
Mar ’22CN¥93.91
CN¥104.30
+11.1%
17.0%CN¥128.57CN¥71.57CN¥64.677
Feb ’22CN¥94.93
CN¥95.58
+0.7%
14.3%CN¥114.29CN¥71.57CN¥64.497
Jan ’22CN¥81.14
CN¥88.27
+8.8%
10.1%CN¥100.00CN¥71.57CN¥74.758

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies